ATE264676T1 - Verwendung von dha in der behandlung von dyslexie - Google Patents
Verwendung von dha in der behandlung von dyslexieInfo
- Publication number
- ATE264676T1 ATE264676T1 AT96919911T AT96919911T ATE264676T1 AT E264676 T1 ATE264676 T1 AT E264676T1 AT 96919911 T AT96919911 T AT 96919911T AT 96919911 T AT96919911 T AT 96919911T AT E264676 T1 ATE264676 T1 AT E264676T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- dyslexia
- dha
- treatment
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9510636.5A GB9510636D0 (en) | 1995-05-25 | 1995-05-25 | Fatty acid treatment |
PCT/GB1996/001265 WO1996037200A1 (en) | 1995-05-25 | 1996-05-24 | Use of dha as a pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE264676T1 true ATE264676T1 (de) | 2004-05-15 |
Family
ID=10775045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96919911T ATE264676T1 (de) | 1995-05-25 | 1996-05-24 | Verwendung von dha in der behandlung von dyslexie |
Country Status (17)
Country | Link |
---|---|
US (1) | US6150411A (de) |
EP (1) | EP0774962B1 (de) |
JP (1) | JPH10503531A (de) |
KR (1) | KR970704433A (de) |
AT (1) | ATE264676T1 (de) |
AU (1) | AU722474B2 (de) |
CA (1) | CA2195979A1 (de) |
DE (1) | DE69632236T2 (de) |
DK (1) | DK0774962T3 (de) |
ES (1) | ES2217317T3 (de) |
FI (1) | FI970298A (de) |
GB (1) | GB9510636D0 (de) |
HK (1) | HK1012575A1 (de) |
NO (1) | NO970317D0 (de) |
PT (1) | PT774962E (de) |
WO (1) | WO1996037200A1 (de) |
ZA (1) | ZA964215B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2292223A1 (de) * | 1998-10-15 | 2011-03-09 | DSM IP Assets B.V. | Polyungesättigen Fettsäuren Nährungsergänzung |
KR100341109B1 (ko) * | 1999-03-10 | 2002-06-20 | 이인수 | 인식력 및 기억력 증강용 식이 조성물 |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US7112609B2 (en) * | 1999-06-01 | 2006-09-26 | Drugtech Corporation | Nutritional supplements |
GB9918023D0 (en) | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
GB9923738D0 (en) * | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
ES2288193T3 (es) | 2001-07-27 | 2008-01-01 | NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. | Fosfolipidos naturales de origen marino que contienen flavonoides y fosfolipidos poliinsaturados y sus usos. |
US20050130937A1 (en) | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
AU2005208832A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB0813599D0 (en) * | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
ES2663714T3 (es) | 2009-10-29 | 2018-04-16 | Acasti Pharma Inc | Composiciones terapéuticas concentradas en fosfolípidos |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
ES2877810T3 (es) * | 2016-06-01 | 2021-11-17 | Nestle Sa | DGLA en la profilaxis de enfermedades alérgicas |
WO2023102170A1 (en) * | 2021-12-02 | 2023-06-08 | The Regents Of The University Of California | Compositions and methods for inhibiting seizures |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
EP0711503A3 (de) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Mit GLA und/oder DGLA angereicherte Milch |
-
1995
- 1995-05-25 GB GBGB9510636.5A patent/GB9510636D0/en active Pending
-
1996
- 1996-05-24 WO PCT/GB1996/001265 patent/WO1996037200A1/en active IP Right Grant
- 1996-05-24 DK DK96919911T patent/DK0774962T3/da active
- 1996-05-24 ES ES96919911T patent/ES2217317T3/es not_active Expired - Lifetime
- 1996-05-24 ZA ZA964215A patent/ZA964215B/xx unknown
- 1996-05-24 AU AU58277/96A patent/AU722474B2/en not_active Ceased
- 1996-05-24 US US08/776,250 patent/US6150411A/en not_active Expired - Lifetime
- 1996-05-24 KR KR1019970700488A patent/KR970704433A/ko active IP Right Grant
- 1996-05-24 EP EP96919911A patent/EP0774962B1/de not_active Expired - Lifetime
- 1996-05-24 DE DE69632236T patent/DE69632236T2/de not_active Expired - Fee Related
- 1996-05-24 AT AT96919911T patent/ATE264676T1/de not_active IP Right Cessation
- 1996-05-24 PT PT96919911T patent/PT774962E/pt unknown
- 1996-05-24 CA CA002195979A patent/CA2195979A1/en not_active Abandoned
- 1996-05-24 JP JP8535515A patent/JPH10503531A/ja not_active Ceased
-
1997
- 1997-01-24 NO NO970317A patent/NO970317D0/no not_active Application Discontinuation
- 1997-01-24 FI FI970298A patent/FI970298A/fi unknown
-
1998
- 1998-12-18 HK HK98113985A patent/HK1012575A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1996037200A1 (en) | 1996-11-28 |
NO970317L (no) | 1997-01-24 |
DK0774962T3 (da) | 2004-08-09 |
NO970317D0 (no) | 1997-01-24 |
JPH10503531A (ja) | 1998-03-31 |
GB9510636D0 (en) | 1995-07-19 |
DE69632236T2 (de) | 2005-04-14 |
AU5827796A (en) | 1996-12-11 |
FI970298A0 (fi) | 1997-01-24 |
CA2195979A1 (en) | 1996-11-28 |
ES2217317T3 (es) | 2004-11-01 |
PT774962E (pt) | 2004-09-30 |
KR970704433A (ko) | 1997-09-06 |
US6150411A (en) | 2000-11-21 |
FI970298A (fi) | 1997-01-24 |
EP0774962B1 (de) | 2004-04-21 |
HK1012575A1 (en) | 1999-08-06 |
DE69632236D1 (de) | 2004-05-27 |
AU722474B2 (en) | 2000-08-03 |
ZA964215B (en) | 1996-12-04 |
EP0774962A1 (de) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69632236D1 (de) | Verwendung von dha in der behandlung von dyslexie | |
ATE163913T1 (de) | Ungesättigte aliphatische dicarbonsäuren | |
DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
DE3684409D1 (de) | Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose. | |
DE68911103T2 (de) | Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis. | |
DE69421778D1 (de) | Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut | |
PT920323E (pt) | Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica | |
DE69202019D1 (de) | Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS. | |
DE69731898D1 (de) | Verwendung von Sulphoquinovosyldiacylglycerols zur Behandlung von entzündlichen Hauterkrankungen | |
DE69314234T2 (de) | Konservierte Polysiloxanemulsion zur Behandlung von Geweben | |
DE69806622T2 (de) | Kosmetische formulierungen zur verhütung und behandlung von haarausfall | |
ATE71143T1 (de) | Verfahren zur stoffwechsel- und/oder wachstumssteigernden behandlung von mikroorganismen sowie vorrichtung zur durchfuehrung des verfahrens. | |
ATE200624T1 (de) | Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis | |
DE3875637D1 (de) | Zusammensetzungen und verfahren zur behandlung von magengeschwueren. | |
ATE136776T1 (de) | Verwendung von heptastigmin zur behandlung der zerebralen ictus | |
ATE97804T1 (de) | Verwendung von fettsaeuren zur behandlung von myalgischer enzephalomyelitis. | |
DE69319140T2 (de) | 4-guanidinobutyramid zur verbesserung des blutkreislaufs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0774962 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |